108 related articles for article (PubMed ID: 19252009)
1. NICE, drug-eluting stents and the limits of trial data.
Mohindra R
Heart; 2009 Mar; 95(6):505-6; author reply 506. PubMed ID: 19252009
[No Abstract] [Full Text] [Related]
2. NICE guidelines for the use of drug-eluting stents: how do we establish worth?
de Belder MA;
Heart; 2008 Dec; 94(12):1646-8. PubMed ID: 18728067
[No Abstract] [Full Text] [Related]
3. Commentary on drug-eluting stents: NICE technology appraisal guidance.
Richardson J; Stevens A; Barnett D; Longson C
Heart; 2008 Dec; 94(12):1650-2. PubMed ID: 18768567
[No Abstract] [Full Text] [Related]
4. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
Messori A; Trippoli S
Heart; 2009 May; 95(10):847. PubMed ID: 19401286
[No Abstract] [Full Text] [Related]
5. Commentary on drug-eluting stents: to use or not to use--that is the question!
Pfisterer ME
Heart; 2008 Dec; 94(12):1648-50. PubMed ID: 18782796
[No Abstract] [Full Text] [Related]
6. DES editorial. Is there a survival benefit?
Thomas DM
Catheter Cardiovasc Interv; 2008 Apr; 71(5):644-5. PubMed ID: 18360857
[No Abstract] [Full Text] [Related]
7. The process of bringing new drug-eluting stents to market will they see the light of day?
Holmes DR; Patel M
JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
[No Abstract] [Full Text] [Related]
8. Drug-eluting versus bare-metal coronary stents: where are we now?
Amoroso NS; Bangalore S
J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of drug-eluting stents in patients with stable coronary artery disease.
Hung CS; Cheng CL; Chao CL; Kao HL; Chen MF; Lin NP
J Formos Med Assoc; 2011 Feb; 110(2):109-14. PubMed ID: 21377065
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting versus bare metal stents--a one horse race?
Meier P; Gurm HS
J Invasive Cardiol; 2010 Jan; 22(1):33-4. PubMed ID: 20048397
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
[TBL] [Abstract][Full Text] [Related]
12. Drug-eluting stents: costs versus clinical benefit.
O'Neill WW; Leon MB
Circulation; 2003 Jun; 107(24):3008-11. PubMed ID: 12821587
[No Abstract] [Full Text] [Related]
13. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention.
Yeh RW; Normand SL; Wolf RE; Jones PG; Ho KK; Cohen DJ; Cutlip DE; Mauri L; Kugelmass AD; Amin AP; Spertus JA
Circulation; 2011 Oct; 124(14):1557-64. PubMed ID: 21900079
[TBL] [Abstract][Full Text] [Related]
14. Treatment of drug-eluting stent restenosis: a sandwich may not be the best combo.
Belardi J
Catheter Cardiovasc Interv; 2008 Apr; 71(5):599. PubMed ID: 18360848
[No Abstract] [Full Text] [Related]
15. Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis.
Piccolo R; Galasso G; Piscione F; Esposito G; Trimarco B; Dangas GD; Mehran R
Am J Cardiol; 2014 Nov; 114(9):1339-46. PubMed ID: 25242363
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
17. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry.
Venkitachalam L; Lei Y; Stolker JM; Mahoney EM; Amin AP; Lindsey JB; Kennedy KF; Pencina MJ; Lopez JJ; Kleiman NS; Cohen DJ;
Circulation; 2011 Aug; 124(9):1028-37. PubMed ID: 21844081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
